VALERITAS INC
BRIDGEWATER, N.J., May 01, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that multiple abstracts supporting its wearable insulin delivery technology have been accepted for presentation at three upcoming annual medical meetings: the American Association of Clinical Endocrinologists (AACE); International Society for Pharmacoeconomics and Outcomes Research (ISPOR); and American Diabetes Association (ADA).
"Making the case for V-Go® Wearable Insulin Delivery Device, through validation from clinical studies, is a high priority at Valeritas,” commented John Timberlake, President and Chief Executive Officer of Valeritas. “The studies to be presented at these conferences build upon our previously published data which together demonstrate the clinical and economic evidence V-Go provides when used by patients on insulin with Type 2 diabetes. We look forward to presenting these data to the diabetes medical community.”
AACE – May 3-7 in Austin, TX
Abstract #242 / Poster #242: The Impact of Utilizing a Novel Insulin Delivery Device in Patients with Type 2 Diabetes
Date: Friday, May 5, 2017
Time: 5:00 p.m. to 6:15 p.m. CDT
Abstract #248 / Poster #248: Achievement of Glycemic Targets in Patients with Uncontrolled Type 2 Diabetes When Switching to a Wearable Insulin Delivery Device for Insulin Delivery
Date: Friday, May 5, 2017
Time: 5:00 p.m. to 6:15 p.m. CDT
ISPOR – May 20-24 in Boston, MA
Abstract #71796 / Poster #PMD31: Evaluation of Real World Clinical and Pharmacy Budget Outcomes when Switching to a Wearable Insulin Delivery Device for Insulin Administration in Patients with Suboptimally Controlled Diabetes – A Retrospective Study
Date: May 23, 2017
Time: 3:45 to 7:45 p.m. EDT
Abstract #71569 / Poster #PMD39: A Prospective Pragmatic Clinical Trial to Compare the Real-World Use of a Wearable Insulin Delivery Device to Standard Treatment Optimization in Type 2 Diabetes Patients with Poor Glycemic Control using Multiple Daily Insulin Injections
Date: May 23, 2017
Time: 3:45 to 7:45 p.m. EDT
ADA – June 9-13 in San Diego, CA
Clinical and Economic Benefits of V-Go in Patients with Type 2 Diabetes Administering Multiple Daily Injections
Type 2 Diabetes Patients in Poor Glycemic Control Using Multiple Daily Insulin Injections (MDI): Lower A1C and Total Daily Insulin Dose (TDD) when Transferring to V-Go vs. Standard of Care (SOC)
A Prospective Pragmatic Clinical Trial to Compare the Real-World Use of V-Go in Type 2 Diabetes Patients
Logistical details of ADA presentations will be available closer to the meeting.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Forward Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group (646)536-7030 / 7017 IR@valeritas.com Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 bprag@delmarconsulting.com Media Contact: Kirsten Thomas The Ruth Group (508)280-6592 PR@valeritas.com
